AVA04-VbP
/ Avacta, Tufts University
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 28, 2020
Avacta’s proprietary TMAC cancer therapy platform demonstrates successful proof-of-concept in pre-clinical study
(Businesswire)
- "Avacta Group plc...is pleased to announce that it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC™, in a pre-clinical animal model of cancer. The study showed that AVA04-VbP outperformed Bavencio (Avelumab), a marketed anti-PD-L1 immunotherapy....animals treated with AVA04-VbP showed a significant reduction in the rate of tumour growth with respect to those treated with Bavencio."
Preclinical
January 28, 2020
Newly added product
(Businesswire)
- Preclinical, Oncology
Pipeline update
1 to 2
Of
2
Go to page
1